Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Gil
Jacek Bil
Dobrin Vassilev

Showing results (1-10 of 220) with videos related to

Pageof 22
Sort By:
Interventional Cardiology (London, England)|March 29, 2018
Dedicated Bifurcation Drug-eluting Stent BiOSS® - A Novel Device for Coronary Bifurcation TreatmentRobert J Gil, Dobrin Vassilev, Jacek Bil
Interventional Cardiology (London, England)|May 8, 2025
BiOSS® Clinical Programme - State of the Art - BiOSS LIM® Stent - The Novel Option for Coronary Bifurcation TreatmentJacek Bil, Robert J Gil, Dobrin Vassilev
Journal of Interventional Cardiology|April 9, 2014
Dedicated bifurcation paclitaxel-eluting stent BiOSS Expert® in the treatment of distal left main stem stenosisJacek Bil, Robert J Gil, Dobrin Vassilev, et al.
Biomedicines|May 25, 2024
The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year ResultsRobert J Gil, Adam Kern, Krystian Bojko, et al.
European Journal of Clinical Investigation|March 30, 2021
6-year results of BiOSS stents in coronary bifurcation treatmentRobert J Gil, Adam Kern, Radoslaw Formuszewicz, et al.
Kardiologia Polska|May 14, 2008
Relative dependence of diameters of branches in coronary bifurcations after stent implantation in main vessel--importance of carina positionDobrin Vassilev, Robert J Gil
The Canadian Journal of Cardiology|April 2, 2015
Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I TrialRobert J Gil, Jacek Bil, Vladimír Džavík, et al.
Cardiovascular Therapeutics|May 16, 2020
Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II StudiesRobert J Gil, Jacek Bil, Adam Kern, et al.
Cardiology Journal|August 26, 2017
Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studiesRobert J Gil, Jacek Bil, Adam Kern, et al.
Journal of Thoracic Disease|September 14, 2016
Bioresorbable vascular scaffolds-what does the future bring?Jacek Bil, Robert J Gil
Pageof 22

Showing results (1-10 of 220) with videos related to

Sort By:
Pageof 22
Interventional Cardiology (London, England)|March 29, 2018
Dedicated Bifurcation Drug-eluting Stent BiOSS® - A Novel Device for Coronary Bifurcation TreatmentRobert J Gil, Dobrin Vassilev, Jacek Bil
Interventional Cardiology (London, England)|May 8, 2025
BiOSS® Clinical Programme - State of the Art - BiOSS LIM® Stent - The Novel Option for Coronary Bifurcation TreatmentJacek Bil, Robert J Gil, Dobrin Vassilev
Journal of Interventional Cardiology|April 9, 2014
Dedicated bifurcation paclitaxel-eluting stent BiOSS Expert® in the treatment of distal left main stem stenosisJacek Bil, Robert J Gil, Dobrin Vassilev, et al.
Biomedicines|May 25, 2024
The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year ResultsRobert J Gil, Adam Kern, Krystian Bojko, et al.
European Journal of Clinical Investigation|March 30, 2021
6-year results of BiOSS stents in coronary bifurcation treatmentRobert J Gil, Adam Kern, Radoslaw Formuszewicz, et al.
Kardiologia Polska|May 14, 2008
Relative dependence of diameters of branches in coronary bifurcations after stent implantation in main vessel--importance of carina positionDobrin Vassilev, Robert J Gil
The Canadian Journal of Cardiology|April 2, 2015
Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I TrialRobert J Gil, Jacek Bil, Vladimír Džavík, et al.
Cardiovascular Therapeutics|May 16, 2020
Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II StudiesRobert J Gil, Jacek Bil, Adam Kern, et al.
Cardiology Journal|August 26, 2017
Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studiesRobert J Gil, Jacek Bil, Adam Kern, et al.
Journal of Thoracic Disease|September 14, 2016
Bioresorbable vascular scaffolds-what does the future bring?Jacek Bil, Robert J Gil
Pageof 22